Guizhou Xinbang Pharma Buys Hangzhou Chinese Peptide for $323 Million

Guizhou Xinbang Pharmaceutical paid $323 million to acquire Chinese Peptide Company, located in Hangzhou, from the nine companies that owned it. In addition, Xinbang raised as much as $106 million, which it will use to expand CPC's peptide production capacity. Founded in 1997, CPC describes itself as a high-quality, reasonable-cost maker of peptides and IVD reagents. More details.... Stock Symbol: (SHE: 002390) Share this with colleagues: // //